Gout is a common problem among renal transplant patients with a prevalence of 2 to 13%.
Hyperuricemia is even more common (1–7). This association is important in two respects …

Abstract Hyperuricaemia occurs in 5–84% and gout in 1.7–28% of recipients of solid organ
transplants. Gout may be severe and crippling, and may hinder the improved quality of life …

Uricase-deficient mice develop uric acid nephropathy, with high mortality rates before
weaning. Urate excretion was quantitated and renal function was better defined in this study …

The pharmacological profile of drugs for hyperuricemia is reviewed. These agents may
reduce the amount of uric acid in blood by means of two different ways:(1) by reducing uric …

Liver transplantation may be indicated in patients with GSD type Ia when dietary treatment
fails or when hepatic adenomas develop, because they carry a risk of liver cancer or severe …

The literature on the pathogenesis of hyperuricemia have been limited to the discussion of
metabolic syndromes associated with risk factors for atherosclerosis and hyperuricemia and …

The entire encoding region for Aspergillus flavus uricase was cloned into pET-32a and
expressed in Escherichia coli BL21 (DE3). The uricase was expressed in the E. coli …

Background: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy
polyethylene glycol that is approved in the US for treatment of patients with chronic refractory …

Background. Although hyperuricaemia and gout are frequently found in renal transplant
recipients, little has been published on the efficacy of urate‐lowering therapy (ULT) in this …

Aims: The aims of the present audit were to determine the prevalence of gout in renal
transplant recipients in Canterbury, New Zealand, to identify risk factors for gout, and to …